

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Gmm

U.S. APPLICATION NUMBER NO. 10/541,626	FIRST NAMED APPLICANT Haruo Hanawa	ATTY. DOCKET NO. 0760-0347PUS1
---	---------------------------------------	-----------------------------------

INTERNATIONAL APPLICATION NO.

PCT/JP03/16956

I.A. FILING DATE 12/26/2003	PRIORITY DATE 01/10/2003
--------------------------------	-----------------------------

2292
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

Docketed

4.23.06

Sequence Listing

CONFIRMATION NO. 8303

371 FORMALITIES LETTER



OC000000018048986

Date Mailed: 02/23/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.


PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/541,626	PCT/JP03/16956	0760-0347PUS1

FORM PCT/DO/EO/922 (371 Formalities Notice)



Docket No.: 0760-0347PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Haruo HANAWA

Application No.: 10/541,626

Confirmation No.: 8303

Filed: July 7, 2005

Art Unit: 1644

For: VECTOR FOR GENE THERAPY AND
METHOD OF QUANTIFYING TARGET
PROTEIN IN MAMMAL OR CULTURED
CELLS WITH THE ADMINISTRATION OF
THE VECTOR FOR GENE THERAPY

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 23, 2006, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This Reply includes:

- Amendments** to the Specification begin on page 2 of this paper.
- Amendments** to the Sequence Listing begin on page 6 of this paper.
- Remarks/Arguments** begin on page 6 of this paper.
- An **Appendix** including the paper and CRF disk copy of the Sequence Listing is attached following page 7 of this paper.



AMENDMENT TRANSMITTAL LETTER

Docket No.
0760-0347PUS1

Application No.
10/541,626-Conf. #8303

Filing Date
July 7, 2005

Examiner
Not Yet Assigned

Art Unit
1644

Applicant(s): Haruo HANAWA

VECTOR FOR GENE THERAPY AND METHOD OF QUANTIFYING TARGET PROTEIN IN
Invention: MAMMAL OR CULTURED CELLS WITH THE ADMINISTRATION OF THE VECTOR FOR
GENE THERAPY

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	16	- 20 =		x	
Independent Claims	6	- 6 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

☒ Large Entity

☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.


☐ A check in the amount of \$ _____ is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-2448
as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.


Gerald M. Murphy, Jr.
Attorney Reg. No.: 28,977

Dated: April 24, 2006

BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000